Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: PTP4A2

Summary for PTP4A2

Gene information	Gene symbol	PTP4A2
	Ensembl ID	ENSG00000184007
	Entrez ID	8073
	Gene name	protein tyrosine phosphatase 4A2
	Synonyms	HU-PP-1\|OV-1\|PRL-2\|PRL2\|ptp-IV1a\|PTP4A\|PTPCAAX2
	Gene type	protein_coding
	UniProtAcc	Q12974

Top

Dataset with differentially expressed gene: PTP4A2

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	0.59302	0.00e+00
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	-0.57245	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.284429	2.03e-39
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.253939	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.340764	1.87e-06
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.261713	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	-0.384871	8.58e-08
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-0.389434	2.02e-21
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	-0.415008	6.48e-28
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	cDCs	-0.292204	4.98e-02
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-0.481872	9.32e-23
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.527685	6.18e-30
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	0.296426	1.46e-21
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	0.287577	1.53e-02
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	0.281248	1.66e-13
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	0.29387	4.59e-20
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	0.27401	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-1.01431	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.381122	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.276395	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Erythrocytes	-0.267226	1.31e-05
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	-0.257495	3.88e-04
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.321744	8.11e-28
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.421489	1.67e-28
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.489955	0.00e+00
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.384998	2.08e-26
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	0.253299	9.03e-41
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD8+ T cells	0.407808	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	0.275128	1.59e-07
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	0.326376	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	0.4101	0.00e+00

Top

Expression of PTP4A2 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to PTP4A2

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating PTP4A2

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
PTP4A2	hsa-miR-5011-5p	100	NM_080391
PTP4A2	hsa-miR-190a-3p	100	NM_001195100
PTP4A2	hsa-miR-8485	99.5252	NM_080391
PTP4A2	hsa-miR-656-3p	98.4921	NM_080391
PTP4A2	hsa-miR-651-3p	98.4618	NM_001195100
PTP4A2	hsa-miR-4307	97.0193	NM_080391
PTP4A2	hsa-miR-4677-5p	96.411	NM_001195100
PTP4A2	hsa-miR-3148	96.4067	NM_001195100
PTP4A2	hsa-miR-6739-3p	92.4898	NM_001195100
PTP4A2	hsa-miR-302a-5p	92.1368	NM_080391
PTP4A2	hsa-miR-627-3p	91.7459	NM_080391
PTP4A2	hsa-miR-12123	91.5343	NM_001195100
PTP4A2	hsa-miR-4314	91.177	NM_001195100
PTP4A2	hsa-miR-642a-5p	89.8435	NM_080391
PTP4A2	hsa-miR-664a-3p	88.1794	NM_001195100
PTP4A2	hsa-miR-627-5p	88.0704	NM_080391
PTP4A2	hsa-miR-548c-3p	87.8867	NM_080391
PTP4A2	hsa-miR-4703-5p	86.8994	NM_001195100
PTP4A2	hsa-miR-6884-3p	86.1526	NM_001195100
PTP4A2	hsa-miR-5584-5p	86.1353	NM_080391
PTP4A2	hsa-miR-6071	85.26	NM_001195100
PTP4A2	hsa-miR-3942-5p	83.8073	NM_001195100
PTP4A2	hsa-miR-6506-5p	83.3017	NM_001195100
PTP4A2	hsa-miR-619-5p	83.3017	NM_001195100
PTP4A2	hsa-miR-4420	83.0566	NM_080391
PTP4A2	hsa-miR-181b-2-3p	83.0566	NM_080391
PTP4A2	hsa-miR-181b-3p	83.0566	NM_080391
PTP4A2	hsa-miR-7156-5p	82.7675	NM_001195100
PTP4A2	hsa-miR-34b-5p	82.6983	NM_001195100
PTP4A2	hsa-miR-449c-5p	82.6983	NM_001195100
PTP4A2	hsa-miR-1294	82.2817	NM_001195100
PTP4A2	hsa-miR-9986	82.2817	NM_001195100
PTP4A2	hsa-miR-186-5p	82.1932	NM_080391
PTP4A2	hsa-miR-4692	81.7659	NM_001195100
PTP4A2	hsa-miR-29b-2-5p	81.5567	NM_001195100
PTP4A2	hsa-miR-6823-5p	81.1224	NM_080391
PTP4A2	hsa-miR-3692-5p	80.3044	NM_001195100

Page: 1

Top

Motifs and transcription factors (TFs) regulating PTP4A2

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
PTP4A2	transfac_pro__M05798	ZNF517 (directAnnotation).
PTP4A2	kznf__ZNF384_Schmitges2016_RCADE	ZNF384 (directAnnotation).
PTP4A2	metacluster_55.3	E2F6; EGR1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; ZBTB2; ZSCAN10 (directAnnotation). NFE2L1; NRF1; NRF1; NRF1 (inferredBy_Orthology).
PTP4A2	metacluster_34.3	EGR1; ETS1; SETDB1; SIX5; SIX5; ZNF143; ZNF76 (directAnnotation).
PTP4A2	transfac_pro__M04950	EGR1 (directAnnotation).
PTP4A2	taipale_tf_pairs__E2F1_ELK1_SGCGCNNNNNNNNNNCGGAAGN_CAP_repr	E2F1; ELK1 (directAnnotation).
PTP4A2	stark__RCGCMATTW	YY1 (inferredBy_Orthology).
PTP4A2	transfac_pro__M06340	ZNF790 (directAnnotation).
PTP4A2	metacluster_144.8	ZNF30; ZNF30 (directAnnotation).
PTP4A2	metacluster_144.3	ZNF704; ZNF704 (directAnnotation).
PTP4A2	tfdimers__MD00154	MZF1; SREBF1 (directAnnotation).
PTP4A2	transfac_pro__M01219	SP1 (directAnnotation). SP3 (inferredBy_Orthology).
PTP4A2	cisbp__M00249	WT1 (directAnnotation).
PTP4A2	cisbp__M01863	ZNF711 (inferredBy_Orthology).
PTP4A2	taipale_tf_pairs__GCM1_ELF1_GTGCGGGCGGAAGTN_CAP_repr	ELF1; GCM1 (directAnnotation).
PTP4A2	homer__GGCGGGAARN_E2F6	E2F6 (directAnnotation).
PTP4A2	taipale_cyt_meth__ZNF460_NRMCGCCCCCCGN_eDBD_meth	ZNF460 (directAnnotation).
PTP4A2	kznf__ZNF571_Imbeault2017_OM_RCADE	ZNF571 (directAnnotation).
PTP4A2	metacluster_2.9	IRF2; IRF2; IRF2; PRDM1; PRDM1 (directAnnotation). PRDM1 (inferredBy_Orthology).
PTP4A2	transfac_pro__M06711	ZNF160 (directAnnotation).
PTP4A2	metacluster_27.20	ZNF708; ZNF787; ZNF787; ZNF85 (directAnnotation).
PTP4A2	taipale_cyt_meth__TLX3_NAATTGNNNNNNNNNNCAATTN_FL_repr	TLX3 (directAnnotation).
PTP4A2	metacluster_197.2	E2F4; E2F7; E2F7; E2F7; E2F8; E2F8 (directAnnotation).
PTP4A2	metacluster_15.3	E2F1; E2F6; E2F8; E2F8; TFDP1 (directAnnotation). E2F3 (inferredBy_Orthology).
PTP4A2	metacluster_141.5	NR3C1; THAP1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY2; YY2; ZNF597 (directAnnotation). YY1; YY1; YY1; YY2; ZFP42 (inferredBy_Orthology).
PTP4A2	kznf__ZNF100_Imbeault2017_RP_RCADE	ZNF100 (directAnnotation).
PTP4A2	metacluster_151.2	ZNF23 (directAnnotation).
PTP4A2	metacluster_151.1	KAT7; PML; SMAD5; TAF1; ZFP37; ZGPAT; ZNF519; ZNF519; ZNF571; ZNF770; ZNF770; ZNF770; ZSCAN22; ZSCAN22 (directAnnotation).
PTP4A2	transfac_pro__M01199	TRIM28 (directAnnotation).
PTP4A2	metacluster_133.1	ZNF304; ZNF304; ZSCAN22 (directAnnotation).
PTP4A2	dbtfbs__ZSCAN30_HEK293_ENCSR768VNZ_merged_N1	ZSCAN30 (directAnnotation).
PTP4A2	taipale_tf_pairs__ETV5_HES7_CCGGAANNNNNNCACGTG_CAP	ETV5; HES7 (directAnnotation).
PTP4A2	flyfactorsurvey__Mad_FlyReg_FBgn0011648	SMAD9 (inferredBy_Orthology).
PTP4A2	dbtfbs__ZNF407_representative_N1	ZNF407 (directAnnotation).
PTP4A2	metacluster_144.5	ZNF610; ZNF610; ZNF610 (directAnnotation).
PTP4A2	taipale_tf_pairs__TFAP2C_E2F8_NNTCCCGCNNNCCNNNGGC_CAP_repr	E2F8; TFAP2C (directAnnotation).
PTP4A2	kznf__ZNF783_Imbeault2017_OM_MEME	ZNF783 (directAnnotation).
PTP4A2	swissregulon__hs__CHD1	CHD1 (directAnnotation).
PTP4A2	kznf__ZNF383_Imbeault2017_OM_RCADE	ZNF383 (directAnnotation).
PTP4A2	kznf__ZNF90_Imbeault2017_OM_RCADE	ZNF90 (directAnnotation).
PTP4A2	metacluster_135.10	MBD2; MBD2; MECP2; MECP2 (directAnnotation).
PTP4A2	kznf__ZNF311_Imbeault2017_OM_MEME	ZNF311 (directAnnotation).
PTP4A2	transfac_pro__M07310	SP5 (directAnnotation).
PTP4A2	jaspar__MA0535.1	SMAD9 (inferredBy_Orthology).
PTP4A2	transfac_pro__M00938	E2F1 (directAnnotation).
PTP4A2	transfac_pro__M04893	TAF1 (directAnnotation).
PTP4A2	transfac_pro__M12697	ZNF142 (directAnnotation).
PTP4A2	metacluster_175.1	ZNF283 (directAnnotation).
PTP4A2	cisbp__M00788	ZFY (inferredBy_Orthology).
PTP4A2	metacluster_23.9	GLIS1; GLIS3; GLIS3; ZNF575 (directAnnotation). GLIS2; GLIS2; GLIS3; ZNF575; ZXDA; ZXDA; ZXDA; ZXDA; ZXDB; ZXDB; ZXDB; ZXDB; ZXDC; ZXDC; ZXDC; ZXDC (inferredBy_Orthology).

Page: 1 2 3 4 5

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."